Market Overview

UPDATE: Maxim Group Initiates Threshold Pharmaceuticals at Buy on Doxorubicin Potential

Related THLD
Threshold Pharma Says Phase 3 Trial of TH-302 in Patients with Advanced Soft Tissue Sarcoma Will Continue as Planned
Events for the Week of Sept. 8-12

Maxim Group initiated coverage on Threshold Pharmaceuticals (NASDAQ: THLD) with a Buy rating and a price target of $10 per share.

Maxim Group commented, "THLD's lead drug, TH-302, is currently in a phase III trial as a first-line treatment with doxorubicin for advanced soft tissue sarcoma (STS) and at the end of a phase IIb trial as a first-line therapy with gemcitabine for pancreatic cancer. Both cancers are difficult-to-treat malignancies with limited chemotherapies on the market. Based on earlier trial results, we believe there is a good chance for THLD to deliver significant improvement of overall survival (OS) in expanded patient populations."

Threshold Pharmaceuticals closed at $7.78 on Wednesday.

Latest Ratings for THLD

DateFirmActionFromTo
Sep 2014Cantor FitzgeraldInitiates Coverage onBuy
Sep 2014HC WainwrightInitiates Coverage onBuy
Feb 2013Piper JaffrayUpgradesNeutralOverweight

View More Analyst Ratings for THLD
View the Latest Analyst Ratings

Posted-In: Maxim GroupAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (THLD)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters